Arvinas (ARVN) Competitors $7.42 -0.02 (-0.27%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.42 +0.00 (+0.07%) As of 08/1/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. IDYA, TWST, GLPG, AGIO, BEAM, VCEL, IRON, HRMY, MESO, and CNTAShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include IDEAYA Biosciences (IDYA), Twist Bioscience (TWST), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Beam Therapeutics (BEAM), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors IDEAYA Biosciences Twist Bioscience Galapagos Agios Pharmaceuticals Beam Therapeutics Vericel Disc Medicine Harmony Biosciences Mesoblast Centessa Pharmaceuticals Arvinas (NASDAQ:ARVN) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Which has more volatility and risk, ARVN or IDYA? Arvinas has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Is ARVN or IDYA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-10.92% -7.74% -4.11% IDEAYA Biosciences N/A -29.28%-27.68% Which has preferable valuation and earnings, ARVN or IDYA? Arvinas has higher revenue and earnings than IDEAYA Biosciences. Arvinas is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.06-$198.90M-$0.66-11.24IDEAYA Biosciences$7M303.65-$274.48M-$3.59-6.76 Does the media favor ARVN or IDYA? In the previous week, IDEAYA Biosciences had 3 more articles in the media than Arvinas. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 5 mentions for Arvinas. IDEAYA Biosciences' average media sentiment score of 0.85 beat Arvinas' score of 0.50 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ARVN or IDYA? Arvinas presently has a consensus price target of $20.29, suggesting a potential upside of 173.44%. IDEAYA Biosciences has a consensus price target of $48.09, suggesting a potential upside of 98.15%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.77 Do institutionals & insiders have more ownership in ARVN or IDYA? 95.2% of Arvinas shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of Arvinas shares are owned by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryArvinas beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$541.59M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.13%P/E Ratio-11.2417.8528.9923.78Price / Sales2.06309.13440.5195.88Price / CashN/A41.6335.0756.59Price / Book0.918.488.255.54Net Income-$198.90M-$55.06M$3.25B$259.97M7 Day Performance-5.36%-3.99%-3.75%-4.67%1 Month Performance-5.97%8.53%2.99%3.29%1 Year Performance-71.28%6.51%25.34%17.92% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.5088 of 5 stars$7.42-0.3%$20.29+173.4%-71.3%$541.59M$263.40M-11.24420News CoverageUpcoming EarningsIDYAIDEAYA Biosciences4.1776 of 5 stars$25.02+2.1%$48.09+92.2%-39.5%$2.19B$7M-6.9780Upcoming EarningsTWSTTwist Bioscience3.5391 of 5 stars$36.53+1.5%$50.40+38.0%-21.6%$2.19B$312.97M-11.24990News CoverageUpcoming EarningsShort Interest ↑Gap DownGLPGGalapagos0.3569 of 5 stars$32.79+0.4%$25.33-22.7%+28.2%$2.16B$275.61M0.001,310AGIOAgios Pharmaceuticals4.0174 of 5 stars$37.20-7.0%$57.33+54.1%-20.4%$2.15B$36.50M3.31390News CoverageEarnings ReportBEAMBeam Therapeutics2.6235 of 5 stars$20.83-4.1%$48.75+134.0%-31.4%$2.09B$63.52M-4.52510News CoverageUpcoming EarningsInsider TradeGap DownVCELVericel2.4355 of 5 stars$41.45+3.3%$61.14+47.5%-25.2%$2.09B$237.22M1,382.13300Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionIRONDisc Medicine3.3948 of 5 stars$59.48-1.9%$95.73+60.9%+37.7%$2.06BN/A-15.1730Upcoming EarningsInsider TradeHRMYHarmony Biosciences4.7391 of 5 stars$35.76-4.7%$51.00+42.6%+6.2%$2.05B$714.73M13.65200Positive NewsUpcoming EarningsMESOMesoblast0.7701 of 5 stars$15.93-2.6%$18.00+13.0%+140.0%$2.04B$5.67M0.0080CNTACentessa Pharmaceuticals3.1992 of 5 stars$15.20-1.4%$28.10+84.9%+66.9%$2.03B$6.85M-8.40200News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies IDYA Competitors TWST Competitors GLPG Competitors AGIO Competitors BEAM Competitors VCEL Competitors IRON Competitors HRMY Competitors MESO Competitors CNTA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts